Compare PNBK & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PNBK | FATE |
|---|---|---|
| Founded | 1999 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 136.8M | 125.6M |
| IPO Year | 2006 | 2013 |
| Metric | PNBK | FATE |
|---|---|---|
| Price | $1.06 | $1.77 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $4.10 |
| AVG Volume (30 Days) | 236.5K | ★ 2.9M |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 98.31 | 29.88 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,646,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.90 | $0.91 |
| 52 Week High | $6.20 | $2.47 |
| Indicator | PNBK | FATE |
|---|---|---|
| Relative Strength Index (RSI) | 38.18 | 50.76 |
| Support Level | N/A | $0.99 |
| Resistance Level | $1.44 | $1.94 |
| Average True Range (ATR) | 0.09 | 0.24 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 12.50 | 42.97 |
Patriot National Bancorp Inc provides consumer and commercial banking services to individuals, small and medium-sized businesses, professionals, and municipalities in Fairfield and New Haven Counties in Connecticut and Westchester County, New York. Its products include checking accounts, savings accounts, money market accounts, time certificates of deposit, and individual retirement accounts. The Bank's lending portfolio is comprised of commercial mortgage and construction loans, commercial loans, home improvement loans, home equity lines of credit, and other personal loans. In addition, the Bank offers bank checks, money orders, automated teller machines, interactive teller machines, online and mobile banking, credit cards, and debit cards.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.